Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
January 23, 2023
Discovering and developing innovative therapies to deliver potentially transformative treatments
Atlantic Re:think Q&A with Samer Ansari, Takeda’s Oncology Business Unit Head of Data, Digital & Technology